Asahi Kasei Pharma today launched new 150 mg and 200 mg subcutaneous autoinjector formulations of Kevzara® [generic name: sarilumab (rDNA origin)] for treatment of rheumatoid arthritis in Japan. Kevzara® is now available for subcutaneous injection by conventional syringe and autoinjection, both of which are subject to a guidance and management fee for self-injection at home.

The Kevzara® autoinjector was developed based on user-centered design for form and function to meet the needs of rheumatoid arthritis patients. Its ergonomic shape is easy to handle, even for patients suffering from joint stiffness, pain, or deformities. Pre-filled with a single dose, Kevzara® autoinjector allows patients to self-administer without seeing the needle, simply by removing the ringed cap and depressing the tip against the skin. Furthermore, it enables patients to confirm completion of the injection not only by a highly visible window on the autoinjector, but also by audible clicking sounds at the beginning and end of injection.

Asahi Kasei Pharma believes that it can make a significant contribution to the treatment of rheumatoid arthritis by providing autoinjection as a new therapeutic option. The company will strive to further improve patients' quality of life by promoting the proper use of all available Kevzara® formulations as well as disseminating relevant information.

Product outline

Product name

Kevzara® 150 mg Subcutaneous Autoinjector
Kevzara® 200 mg Subcutaneous Autoinjector

Generic name

Sarilumab (rDNA origin)

Indication

Rheumatoid arthritis not responding well to conventional treatments

Dosage and administration

For adults, ordinarily subcutaneous administration of 200 mg of sarilumab (rDNA origin) once every 2 weeks. Reduced to 150 mg depending on patient condition.

Manufacture

Sanofi K.K.

Sale

Asahi Kasei Pharma Corp.

Approval

September 27, 2017

NHI price listing

November 28, 2018

Launch of sale

December 11, 2018

NHI price

¥44,945 per 150 mg autoinjection kit
¥59,509 per 200 mg autoinjection kit

News